Tuesday, July 14, 2015

10 Best Building Product Stocks To Watch Right Now

10 Best Building Product Stocks To Watch Right Now: Kite Pharma Inc (KITE)

Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT). eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs, or T cell receptors, or TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Company funds multiple Phase I-2a clinical trials with CAR- and TCR-based therapies that are being conducted by its collaborator, the Surgery Branch of the National Cancer Institute (NCI). The Company plans to conduct a Phase I-2 clinical trial for its lead product candidate KTE-C19, a CAR-based therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).

eACT involves harvesting T cells from the patient's blood; genetically engineering T cells to express cancer-specific receptors; increasing the number of engineered T cells and infusing the functional cancer-specific T cells back into the patient. Using eACT technology, T cells can be genetically modified to express one of two classes of cancer-specific receptors: CARs or TCRs. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. TCRs broaden the therapeutic approach by recognizing fragments on the cancer cell surface derived from intracellular proteins. By combining both CAR and TCR approaches, it has the potential to generate a portfolio of products that can target both solid and hematological tumors. It has a Cooperative Research and Development Agreement (CRADA), through which it is funding the research and development o! f eACT-based product candidates utilizing CARs and TCRs for the treatment of advanced solid and hematological malignancies.

The Company's lead product candidate, KTE-C19, ! is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias. The Company is an ongoing NCI Phase I-2a clinical trial utilizing anti-CD19 CAR T cell therapy that is designed to establish a dose level and appropriate conditioning regimen, as well as to assess overall safety, in patients with B cell lymphomas and leukemias that had been heavily pretreated and were relapsed/refractory (unresponsive) to chemotherapy. KTE-C19 will use the identical anti-CD19 CAR construct and viral vector that is being used in the NCI trial. The Company a license with the NIH for intellectual property relating to a TCR-based T cell therapy targeting the antigen SSX2 for the treatment of head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer and sarcoma, and a co-exclusive license to this intellectual property for the treatment of certain additional cancer types.

Advisors' Opinion:
  • [By John Udovich]

    Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN) involving Chimeric Antigen Receptors (CAR) – meaning its worth taking a closer look at the stock, which had an IPO last June, along with potential peers Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

  • [By Matt Egan]

    While the health-care sector only raised $1.8 billion during the second quarter, it led the way with 24 IPOs, up from 17 the year before. Hot drug IPOs include Zs Pharma (ZSPH), Kite Pharma (KITE) and GlobeImmune (GBIM), all of which debuted in June and are trading more than 40% above their IPO price.

  • [By! John Udo! vich]

    Biotech news this week was dominated by a number of healthcare and biotech related IPOs, including Parnell Pharmaceuticals Holdings Ltd (NASDAQ: PARN), Signal Genetics Inc (NASDAQ: SGNL), ZS Pharma Inc (NASDAQ: ZSPH), Ardelyx Inc (NASDAQ: ARDX) and Zafgen Inc (NASDAQ: ZFGN) with Kite Pharma Inc (NASDAQ: KITE), Microlin Bio Inc (NASDAQ: MCLB) and Syndax Pharmaceuticals Inc (NASDAQ: SNDX) presumably set to debut today (Note: See This Week's Biotech IPOs: Two Losers and One Winner So Far (PARN, SGNL & ZSPH)):

  • source from Top Stocks For 2015:http://www.topstocksblog.com/10-best-building-product-stocks-to-watch-right-now-4.html

No comments:

Post a Comment